Accurate assessment of adherence: Self-report and clinician report vs electronic monitoring of nebulizers

Chest

Volumn 140, Issue 2, 2011, Pages 425-432

  Daniels, Tracey ^a   Goodacre, Lynne ^b   Sutton, Chris ^b   Pollard, Kim ^c   Conway, Steven ^c   Peckham, Daniel ^c  

^a YORK HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; DORNASE ALFA; IPRATROPIUM BROMIDE; SALBUTAMOL; SODIUM CHLORIDE; TOBRAMYCIN;

ACCURACY; ADULT; ARTICLE; CLINICIAN REPORT; CYSTIC FIBROSIS; ELECTRONIC MONITORING; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MONITORING; NEBULIZER; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SELF REPORT;

EID: 79958257149     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-3074     Document Type: Article

References (29)

1. Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev. 2005;4(4):CD003428.
2. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009;8(2):91-96.
3. Dodd ME, Webb AK. Understanding non-compliance with treatment in adults with cystic fibrosis. J R Soc Med. 2000;93(suppl 38):2-8. (Pubitemid 30311439)
4. Quittner AL, Modi AC, Lemanek KL, Ievers-Landis CE, Rapoff MA. Evidence-based assessment of adherence to medical treatments in pediatric psychology. J Pediatr Psychol. 2008;33(9):916-936, discussion 937-938.
5. Glasscoe CA, Quittner AL. Psychological interventions for people with cystic fibrosis and their families. Cochrane Database Syst Rev. 2008;3(3):CD003148.
6. Koocher GP, McGrath ML, Gudas LJ. Typologies of nonadherence in cystic fibrosis. J Dev Behav Pediatr. 1990;11(6):353-358.
7. Conway SP, Pond MN, Hamnett T, Watson A. Compliance with treatment in adult patients with cystic fibrosis. Thorax. 1996;51(1):29-33. (Pubitemid 26047099)
8. Abbott J, Dodd M, Bilton D, Webb AK. Treatment compliance in adults with cystic fibrosis. Thorax. 1994;49(2):115-120.
9. Passero MA, Remor B, Salomon J. Patient-reported compliance with cystic fibrosis therapy. Clin Pediatr (Phila). 1981;20(4):264-268. (Pubitemid 11117571)
10. Lask B. Non-adherence to treatment in cystic fibrosis. J R Soc Med. 1994;87(87) (suppl 21):25-27. (Pubitemid 24153682)
11. Kettler LJ, Sawyer SM, Winefield HR, Greville HW. Determinants of adherence in adults with cystic fibrosis. Thorax. 2002;57(5):459-464. (Pubitemid 34494161)
12. Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner ALA. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros. 2006;5(3):177-185. (Pubitemid 44063951)
13. Brennan VK, Osman LM, Graham H, Critchlow A, Everard ML. True device compliance: the need to consider both competence and contrivance. Respir Med. 2005;99(1):97-102. (Pubitemid 40017391)
14. Everard ML. Regimen and device compliance: key factors in determining therapeutic outcomes. J Aerosol Med. 2006;19(1):67-73.
15. Dodd ME, Haworth CS, Webb AK. The medical and economic consequences of non-compliance in clinical trials and in primary care [Abstract]. Thorax. 1998;53(suppl 4):A18. (Pubitemid 128777331)
16. Riekert KA, Rand CS. Electronic monitoring of medication adherence: when is high tech best? J Clin Psychol Med Settings. 2002;9(1):25-34. (Pubitemid 34436401)
17. Denyer J, Dyche T. The adaptive aerosol delivery (AAD) technology: past, present and future J Aerosol Med Pulm Drug Deliv. 2010;23(suppl 1):s1-s10.
18. Nikander K, Prince I, Hinch S. Use of I-Neb Insight to examine patient logging system data from a 3-month evaluation of the I-Neb AAD system. Respir Drug Del. 2008;3:735-738.
19. Prince I, Denyer J, Nikander K. I-Neb Insight: a new tool for monitoring inhaled medication use. Eur Respir J. 2006;28(suppl 50):261s.
20. Archer MJ, Williams V, Rayner RJ. An adherence study using data from an AAD device in cystic fibrosis comparing early and late diagnosis [Abstract]. J Cyst Fibros. 2010; 9 (suppl 1): S12.
21. McNamara PS, McCormack P, McDonald AJ, Heaf L, Southern KW. Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis. J Cyst Fibros. 2009;8(4):258-263.
22. Latchford G, Duff A, Quinn J, Conway S, Conner M. Adherence to nebulised antibiotics in cystic fibrosis. Patient Educ Couns. 2009;75(1):141-144.
23. Burrows JA, Bunting JP, Masel PJ, Bell SC. Nebulised dornase alpha: adherence in adults with cystic fibrosis. J Cyst Fibros. 2002;1(4):255-259.
24. Wagner GJ, Ghosh-Dastidar B. Electronic monitoring: adherence assessment or intervention? HIV Clin Trials. 2002;3(1):45-51. (Pubitemid 34183095)
25. Rosenstein BJ, Cutting GR;Cystic Fibrosis Foundation Consensus Panel. The diagnosis of cystic fibrosis: a consensus statement. J Pediatr. 1998;132(4):589-595. (Pubitemid 28194575)
26. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307-310. (Pubitemid 16134762)
27. Rand CS. Patient adherence with COPD therapy. Eur Resp Rev. 2005;14(96):97-101. (Pubitemid 43028766)
28. Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol. 2006;31(8):846-858. (Pubitemid 44310212)
29. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-1224. (Pubitemid 38579798)